Markets:

Overview

News

Currencies

International

Treasuries

Edesa Biotech, Inc. - Common Shares (NQ:EDSA)

6.560 -0.270 (-3.95%)

Streaming Delayed Price Updated: 2:41 PM EDT, Jun 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Edesa Biotech, Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >

Recap: Edesa Biotech Q4 Earnings ↗

December 28, 2021

Edesa Biotech (NASDAQ:EDSA) reported its Q4 earnings results on Tuesday, December 28, 2021 at 04:15 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Edesa Biotech Reports Fiscal Year 2021 Results

December 28, 2021

TORONTO, ON / ACCESSWIRE / December 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported...

From Edesa Biotech

Via AccessWire

Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2021 ↗

December 20, 2021

Upgrades According to Keefe, Bruyette & Woods, the prior rating for Old National Bancorp (NASDAQ:...

Via Benzinga

How To Play Edsa Biotech's Stock After 60% Surge ↗

September 20, 2021

Edsa Biotech Inc. (NASDAQ:EDSA) shares are trading higher ...

Via Benzinga

Edesa Biotech Marks Enrollment Milestone in Dermatitis Study

December 01, 2021

TORONTO, ON / ACCESSWIRE / December 1, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it...

From Edesa Biotech

Via AccessWire

Topics Intellectual Property

Edesa Biotech Extends COVID-19 Clinical Study to Poland

November 04, 2021

- Expansion to European Union country follows favorable Phase 2 results - Company focusing on critically ill hospitalized patients TORONTO, ON / ACCESSWIRE / November 4, 2021 / Edesa Biotech, Inc....

From Edesa Biotech

Via AccessWire

Topics Intellectual Property

Edesa Biotech Shares Gain As Its COVID-19 Antibody Shows Favorable Mortality Reductions ↗

October 19, 2021

Edesa Biotech Inc (NASDAQ: EDSA) has announced additional results from the Phase 2 part of an ongoing Phase 2/3 study of EB05 as a single-dose treatment for hospitalized...

Via Benzinga

Edesa Biotech Is Now Above Resistance: Can It Continue Higher? ↗

October 19, 2021

Edesa Biotech Inc. (NASDAQ: EDSA) shares are trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in...

Via Benzinga

Why Edesa Biotech Shares Are Trading Higher Today ↗

October 19, 2021

Edesa Biotech Inc (NASDAQ: EDSA) is trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in...

Via Benzinga

Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study

October 19, 2021

- Mortality reductions demonstrated across multiple patient groups - Additional efficacy signals recorded in a broad range of mild to severe ARDS patients - Company to focus on critically ill...

From Edesa Biotech

Via AccessWire

Topics Intellectual Property

50 Biggest Movers From Yesterday ↗

September 22, 2021

Check out these big penny stock gainers and losers Losers Edesa Biotech, Inc. (NASDAQ: EDSA) shares dipped 29.9% to close at $8.36 on profit-taking after the stock...

Via Benzinga

Mid-Afternoon Market Update: Dow Edges Lower; Helbiz Shares Spike Higher ↗

September 21, 2021

Toward the end of trading Tuesday, the Dow traded down 0.11% to 33,932.34 while the NASDAQ rose 0.18% to 14,740.41. The S&P also fell, dropping 0.09% to 4,353.81. The U.S. has...

Via Benzinga

Topics Stocks

Mid-Day Market Update: Gold Rises 1%; Verrica Pharmaceuticals Shares Slide ↗

September 21, 2021

Midway through trading Tuesday, the Dow traded up 0.44% to 34,119.86 while the NASDAQ rose 0.66% to 14,810.89. The S&P also rose, gaining 0.43% to 4,376.48. The U.S. has the...

Via Benzinga

Topics Stocks

32 Stocks Moving In Tuesday's Mid-Day Session ↗

September 21, 2021

Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 177.4% to $39.83. Helbiz Media, the media arm of Helbiz announced a deal with Amazon Italy, a unit of Amazon.com. ReWalk...

Via Benzinga

Mid-Morning Market Update: Markets Gain; AutoZone Earnings Beat Views ↗

September 21, 2021

Following the market opening Tuesday, the Dow traded up 0.14% to 34,017.77 while the NASDAQ rose 0.39% to 14,771.47. The S&P also rose, gaining 0.18% to 4,365.67. The U.S. has...

Via Benzinga

Topics Earnings Stocks

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data ↗

September 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics...

Via Benzinga

18 Stocks Moving in Tuesday's Pre-Market Session ↗

September 21, 2021

Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 37% to $1.78 in pre-market trading after declining around 4% on Monday. ReWalk Robotics, last month, reported Q2 sales of $1.44...

Via Benzinga

48 Biggest Movers From Yesterday ↗

September 21, 2021

Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized...

Via Benzinga

EDSA Stock: The Covid-19 News Sending Edesa Biotech Soaring on Monday ↗

September 20, 2021

Today, the announcement of positive clinical trial results has sent investors in Edesa Biotech and EDSA stock on a nice ride.

Via InvestorPlace

Why Edesa Biotech Shares Are Soaring Today ↗

September 20, 2021

Edesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients...

Via Benzinga

Mid-Afternoon Market Update: Dow Tumbles 2.5%; BeyondSpring Shares Plunge ↗

September 20, 2021

Toward the end of trading Monday, the Dow traded down 2.57% to 33,696.98 while the NASDAQ fell 3.14% to 14,572.25. The S&P also fell, dropping 2.58% to 4,318.67. The U.S. has...

Via Benzinga

Topics Stocks

Edesa Biotech Stock Is Rallying After COVID-19 Antibody Data: What You Need To Know ↗

September 20, 2021

Edesa Biotech Inc (NASDAQ: EDSA) has announced positive results from the Phase 2 part of an ongoing Phase 2/3 study evaluating EB05 as a single-dose treatment for...

Via Benzinga

Mid-Day Market Update: Crude Oil Down 2%; Synlogic Shares Spike Higher ↗

September 20, 2021

Midway through trading Monday, the Dow traded down 1.51% to 34,063.71 while the NASDAQ fell 2.13% to 14,723.20. The S&P also fell, dropping 1.64% to 4,360.41. The U.S. has the...

Via Benzinga

Topics Stocks

35 Stocks Moving In Monday's Mid-Day Session ↗

September 20, 2021

Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. (NASDAQ: EDSA) jumped 30.6% to $7.68 after the company...

Via Benzinga

Mid-Morning Market Update: Markets Open Lower; Brooks Automation Divests Semiconductor Business For $3B ↗

September 20, 2021

Following the market opening Monday, the Dow traded down 1.42% to 34,093.46 while the NASDAQ fell 1.86% to 14,763.93. The S&P also fell, dropping 1.54% to 4,364.65. The U.S....

Via Benzinga

Topics Stocks

Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients

September 20, 2021

- Study unblinded due to strong efficacy signal for 28-day mortality endpoint - Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over Standard of Care...

From Edesa Biotech

Via AccessWire

Topics Intellectual Property

Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference

September 09, 2021

TORONTO, ON / ACCESSWIRE / September 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that...

From Edesa Biotech

Via AccessWire

Topics Intellectual Property

Edesa Biotech Provides Update For COVID-19 Antibody Trial ↗

August 26, 2021

Edesa Biotech Inc (NASDAQ: EDSA) issued an update for the Phase 2/3 study evaluating its monoclonal antibody candidate, EB05, as single-dose therapy for...

Via Benzinga

Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule

August 26, 2021

- Delta variant contributes to rapid enrollment amid growing scientific rationale for targeting Toll-like Receptor 4 (TLR4) Blinded interim analysis from Phase 2/3 study expected in current quarter...

From Edesa Biotech

Via AccessWire

Topics Intellectual Property

Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results

August 13, 2021

TORONTO, ON / ACCESSWIRE / August 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial...

From Edesa Biotech

Via AccessWire

Topics Intellectual Property

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.